Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

Abstract

Abstract Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.

Keywords

• diabetes
• euglycemic diabetic ketoacidosis
• sodium‐glucose cotransporter 2 inhibitors